S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.38 (+0.40%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   390.06 (+3.10%)
NIO   7.40 (-1.73%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.76 (+0.19%)
F   12.05 (+0.42%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.56%)
GE   103.72 (+2.16%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.13 (+0.29%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.38 (+0.40%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   390.06 (+3.10%)
NIO   7.40 (-1.73%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.76 (+0.19%)
F   12.05 (+0.42%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.56%)
GE   103.72 (+2.16%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.13 (+0.29%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.38 (+0.40%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   390.06 (+3.10%)
NIO   7.40 (-1.73%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.76 (+0.19%)
F   12.05 (+0.42%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.56%)
GE   103.72 (+2.16%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.13 (+0.29%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.38 (+0.40%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   390.06 (+3.10%)
NIO   7.40 (-1.73%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.76 (+0.19%)
F   12.05 (+0.42%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.56%)
GE   103.72 (+2.16%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.13 (+0.29%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
NYSE:PATH

UiPath (PATH) Stock Forecast, Price & News

$17.37
-0.52 (-2.91%)
(As of 10:58 AM ET)
Compare
Today's Range
$16.69
$17.51
50-Day Range
$12.51
$17.90
52-Week Range
$10.40
$22.30
Volume
6.73 million shs
Average Volume
7.10 million shs
Market Capitalization
$9.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.87

UiPath MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
5.4% Upside
$18.87 Price Target
Short Interest
Bearish
8.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of UiPath in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$2.53 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Business Services Sector

188th out of 347 stocks

Prepackaged Software Industry

116th out of 219 stocks


PATH stock logo

About UiPath (NYSE:PATH) Stock

UiPath Inc. is a leading software company specializing in robotic process automation (RPA) technology. Headquartered in New York City, but founded in Bucharest, Romania, UiPath offers a comprehensive platform that automates repetitive tasks and enables businesses to operate more efficiently. The company was founded in 2005 by Romanian entrepreneurs Daniel Dines and Marius Tirca and has since grown to become a significant player in the RPA industry. UiPath has received numerous awards and accolades, including being named a leader in the Gartner Magic Quadrant for RPA Software in 2020.

UiPath's executive team is led by Chief Executive Officer and co-founder Daniel Dines, who has been with the company since its inception. Daniel is considered one of the pioneers of robotic process automation, helping start the industry. Mr. Dines contributes to his success in the industry by being relentless and constantly exposing himself to the industry's uncertainties. Other key management team members include Chief Financial Officer Ashim Gupta and Chief Marketing Officer Bobby Patrick. In 2021, UiPath announced that former Microsoft executive Tom Clancy would join as its new Senior Vice President of Learning.

UiPath has experienced significant growth in recent years, with revenue increasing exponentially since its inception. The company's net loss has been decreasing yearly. As of January 31, 2021, UiPath has cash, cash equivalents, and short-term investments capable of covering liabilities indicating that the company is working to keep control of its debt. UiPath's valuation has fluctuated since its IPO, with the company's market capitalization reaching a high of over $45 billion in May 2021 before falling to around $10 billion in Q4 of 2022. UiPath's price-to-sales ratio is higher than the industry average. Since its IPO in April 2021, UiPath's stock price has been volatile, with shares reaching a high of $90 in May 2021 before dropping to around $10 in November 2022. Since hitting its all-time low price, the stock has rebounded. Trading volume has also been relatively high, with an average of over 6 million shares traded per day.

The robotic process automation industry has experienced rapid growth in recent years as businesses seek to automate manual processes and increase efficiency. UiPath competes with several other robotic process automation providers, including Automation Anywhere, Blue Prism, and WorkFusion. In addition, the industry is subject to regulatory and political pressures, particularly around data privacy and security.

UiPath has identified several critical areas for growth, including expanding its product offerings to include artificial intelligence and machine learning capabilities and targeting new industries such as healthcare and financial services. The company has also been actively pursuing acquisitions, with recent purchases including Cloud Elements and ProcessGold.

As the robotic process automation industry continues to evolve, UiPath may face challenges from competitors who can offer similar or better technology at a lower cost. In addition, regulatory and political pressures may create uncertainty for the industry, which could impact UiPath's growth prospects.

Receive PATH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UiPath and its competitors with MarketBeat's FREE daily newsletter.

PATH Stock News Headlines

UiPath Stock Has Short-Term Pain for Long-Term AI Gain
UiPath Inc. shares took an initial dive on its fiscal Q1 2024 earnings release. The culprit was lowered fiscal Q2 2024 revenue guidance that spooked investors
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
UiPath Inc. (NYSE:PATH) CAO Sells $220,307.76 in Stock
UiPath Inc. (NYSE:PATH) CFO Ashim Gupta Sells 40,000 Shares
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Should You Buy UiPath Stock Right Now?
UiPath (NYSE:PATH) Shares Gap Down After Analyst Downgrade
Expert Ratings for UiPath
UiPath (PATH) Gets a Hold from Barclays
Q1 2024 UiPath Inc Earnings Call
See More Headlines

PATH Price History

PATH Company Calendar

Last Earnings
3/15/2023
Today
6/01/2023
Next Earnings (Estimated)
9/05/2023
Fiscal Year End
1/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
2,863
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$18.87
High Stock Price Forecast
$27.50
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+5.4%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$-328,350,000.00
Pretax Margin
-30.00%

Debt

Sales & Book Value

Annual Sales
$1.06 billion
Book Value
$3.45 per share

Miscellaneous

Free Float
379,717,000
Market Cap
$9.98 billion
Optionable
Not Optionable
Beta
0.69

Social Links


Key Executives

  • Mr. Daniel Solomon Dines (Age 51)
    Co-Founder, Co-CEO & Chairman
    Comp: $669.65k
  • Mr. Ashim  GuptaMr. Ashim Gupta (Age 44)
    Chief Financial Officer
    Comp: $642.52k
  • Mr. Ted  KummertMr. Ted Kummert (Age 60)
    Exec. VP of Products & Engineering
    Comp: $672.56k
  • Mr. Robert Enslin (Age 60)
    Co-Chief Exec. Officer
  • Mr. Marius Tirca
    Co-Founder & CTO
  • Ms. Kelsey Doherty Turcotte
    Sr. VP of Investor Relations
  • Mr. Brad C. BrubakerMr. Brad C. Brubaker (Age 59)
    Gen. Counsel, Chief Legal Officer & Sec.
  • Mr. Robert B. Patrick (Age 51)
    Chief Marketing Officer
  • Mr. Christopher Townsend
    VP of Federal Sales
  • Mr. Vijay Khanna
    Chief Corp. Devel. Officer













PATH Stock - Frequently Asked Questions

Should I buy or sell UiPath stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UiPath in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PATH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PATH, but not buy additional shares or sell existing shares.
View PATH analyst ratings
or view top-rated stocks.

What is UiPath's stock price forecast for 2023?

15 analysts have issued 12 month price targets for UiPath's stock. Their PATH share price forecasts range from $14.00 to $27.50. On average, they predict the company's stock price to reach $18.87 in the next year. This suggests a possible upside of 11.1% from the stock's current price.
View analysts price targets for PATH
or view top-rated stocks among Wall Street analysts.

How have PATH shares performed in 2023?

UiPath's stock was trading at $12.71 at the start of the year. Since then, PATH shares have increased by 33.7% and is now trading at $16.99.
View the best growth stocks for 2023 here
.

When is UiPath's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 5th 2023.
View our PATH earnings forecast
.

How were UiPath's earnings last quarter?

UiPath Inc. (NYSE:PATH) issued its quarterly earnings data on Wednesday, March, 15th. The healthcare company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The healthcare company had revenue of $308.55 million for the quarter, compared to analyst estimates of $278.14 million. UiPath had a negative net margin of 21.55% and a negative trailing twelve-month return on equity of 10.18%.

What guidance has UiPath issued on next quarter's earnings?

UiPath issued an update on its second quarter 2024 earnings guidance on Saturday, May, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $279.00 million-$284.00 million, compared to the consensus revenue estimate of $283.93 million.

When did UiPath IPO?

(PATH) raised $990 million in an IPO on Wednesday, April 21st 2021. The company issued 21,300,000 shares at a price of $43.00-$50.00 per share. Morgan Stanley, JPMorgan, BofA Securities, Credit Suisse, Barclays and Wells Fargo Securities served as the underwriters for the IPO and SMBC Nikko, BMO Capital Markets, Mizuho Securities USA, KeyBanc Capital Markets, TD Securities (USA), Truist SecuritiesCowen, Evercore Group, Macquarie Capital (USA), Nomura, RBC Capital Markets, Canaccord Genuity, D. A. Davidson & Co., Oppenheimer & Co. and Needham & Co. were co-managers.

What is UiPath's stock symbol?

UiPath trades on the New York Stock Exchange (NYSE) under the ticker symbol "PATH."

Who are UiPath's major shareholders?

UiPath's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (8.05%), Sumitomo Mitsui Trust Holdings Inc. (4.75%), Nikko Asset Management Americas Inc. (4.74%), BlackRock Inc. (3.17%), FMR LLC (2.26%) and State Street Corp (0.99%). Insiders that own company stock include Ashim Gupta, Brad Brubaker, Daniel Dines, East Fund 2013 Sca Sic Digital, Hitesh Ramani, Kimberly Hammonds, Laela Sturdy, Philippe Botteri, Rich Wong, Ted Kummert and Thomas Neergaard Hansen.
View institutional ownership trends
.

How do I buy shares of UiPath?

Shares of PATH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UiPath's stock price today?

One share of PATH stock can currently be purchased for approximately $16.99.

How much money does UiPath make?

UiPath (NYSE:PATH) has a market capitalization of $9.47 billion and generates $1.06 billion in revenue each year. The healthcare company earns $-328,350,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does UiPath have?

The company employs 2,863 workers across the globe.

Does UiPath have any subsidiaries?
The following companies are subsidiares of UiPath: Cloud Elements, Cloud Elements Inc., CloudElements Technologies India Private Limited, MagnaView BV, ProcessGold A.G., ProcessGold B.V., ProcessGold International B.V., Re:infer, Shanghai Zhicheng Technology Co. Ltd., StepShot, The Conundrum IP LLC, UiPath AB, UiPath Australia Pty Ltd, UiPath Austria GmbH, UiPath Belgium BVBA, UiPath Brasil Consultoria Limitada, UiPath Business Solutions India Private Limited, UiPath Canada Operations Ltd., UiPath Denmark ApS, UiPath Finland Oy, UiPath France SAS, UiPath GMBH, UiPath Inc., UiPath Israel LTD, UiPath Italy SRL, UiPath Kabushiki Kaisha, UiPath Korea Ltd., UiPath Limited (Hong Kong), UiPath Ltd. (UK), UiPath Mexico S. DE R.L. DE C.V., UiPath Netherlands B.V., UiPath Netherlands Holding B.V., UiPath Norway AS, UiPath OOO, UiPath PTE LTD, UiPath Process Mining, UiPath Robotic Process Automation India Private Limited, UiPath SRL, UiPath South Africa (Pty) LTD, UiPath Switzerland GmbH, UiPath Ukraine LLC, and UiPath Ventures LLC.
Read More
How can I contact UiPath?

UiPath's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The official website for the company is www.uipath.com. The healthcare company can be reached via phone at 844-432-0455 or via email at investor.relations@uipath.com.

This page (NYSE:PATH) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -